Drugs / PF-04603629
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00637338 | Apr → Sep 2008 | type 2 diabetes mellitus | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00638313 | Aug 2007 → Feb 2008 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-04603629 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00637338 ↗ |
| Known as | BRX-1177 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802178 ↗ |
| Modality | Protein / enzyme biologic | “PF-04603629 is a protein” NCT00637338 ↗ |
| Route | Subcutaneous | “multiple escalating subcutaneous doses” NCT00637338 ↗ |